Evidence map›Paper›PMID 27391367›Full record

ReviewBritish journal of haematology2016

What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.

Annalynn M Williams, Clive S Zent, Michelle C Janelsins

Registry-linked trialAbstract readReview
In one paragraph

Review in British journal of haematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04917783 (Health Literacy), which is not on this map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04917783 nacompletednot on this mapstarted 2019, after this paper: background citation

Health Literacy: A Randomized Controlled Trial to Investigate a Novel Feedback Tool for Neurocognitive Screening in Pediatric Sickle Cell Disease

TypeinterventionalSponsorMedical College of WisconsinRan2019 to 2021Enrolled46ConditionsSickle Cell DiseaseArmsPassport Card, No Passport card
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma undergoing standard chemotherapy: a longitudinal feasibility study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Long-term neurocognitive effects of chimeric antigen receptor T-cell therapy: Integrating assessments into nursing practice.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Annalynn M WilliamsDepartment of Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Clive S ZentWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Michelle C JanelsinsWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.

Funding

Clinical and Translational Approaches to Cognitive Impairments in CancerDP2CA195765 · NCI · UNIVERSITY OF ROCHESTER · PI JANELSINS, MICHELLE C · 2014 to 2014
$2.3M
Interventions Targeting Inflammation for Chemotherapy-Related Cognitive ProblemsK07CA168886 · NCI · UNIVERSITY OF ROCHESTER · PI JANELSINS, MICHELLE C · 2013 to 2017
$724k
NCI NIH HHS DP2 CA195765NCI NIH HHS K07 CA168886
6 · The paper itself

Abstract

Cancer-related cognitive impairment (CRCI) is an important clinical problem for cancer patients and survivors. In this review, we summarize studies investigating the occurrence of impaired cognition in patients with haematological malignancies. Most published studies focus on survivors of childhood acute lymphoblastic leukaemia and primary central nervous system lymphoma. We also discuss studies conducted in acute myeloid leukaemia, myelodysplastic syndromes, chronic myeloid leukaemia, Hodgkin lymphoma (HL), non-HL and chronic lymphocytic leukaemia. Although research in this area is still emerging, it appears that a subset of chemotherapy-treated haematological malignancy survivors experience CRCI. Future research should focus on expanding the literature reviewed here with larger studies appropriately powered to assess cognition via objective and subjective measures in a longitudinal fashion to tease apart the impact of disease and the various forms of cancer treatment.

Indexed as

AnimalsAntineoplastic AgentsCognitionCognitive DysfunctionCombined Modality TherapyDisease ManagementHematologic NeoplasmsHumansRisk FactorsAntineoplastic Agentscancerchemotherapychemotherapy-related cognitive impairmentcognitionhaematological malignancy

Identifiers

PMID27391367
PMCPMC5626568

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.